<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03261453</url>
  </required_header>
  <id_info>
    <org_study_id>TRL-1000-0002</org_study_id>
    <nct_id>NCT03261453</nct_id>
  </id_info>
  <brief_title>THE ENLIGHTEN STUDY</brief_title>
  <official_title>A Randomized, Multi-Center, Phased, Pivotal Safety and Efficacy Study Comparing the Elipse™ Gastric Balloon System vs. Sham for the Treatment of Obese Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allurion Technologies</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allurion Technologies</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to demonstrate the safety and efficacy of the Elipse
      Gastric Balloon System for the treatment of obese adults.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, double-blinded, randomized, two-phase study to be conducted in a
      planned 400 obese individuals drawn from up to 15 sites. The treatment duration of the study
      is 48 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2018</start_date>
  <completion_date type="Anticipated">May 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Co-Primary Effectiveness Endpoint: Total Body Weight Loss (TBWL) Comparison Between Treatment and Control Group at 16 weeks</measure>
    <time_frame>16 weeks</time_frame>
    <description>An inferential test of whether the Treatment Group Responder Rate (RR) dichotomized at 5% TBWL at 16 weeks is significantly greater than 35%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Co-Primary Effectiveness Endpoint 2: Percent of Total Body Weight Loss (TBWL) Comparison Between Treatment and Control group</measure>
    <time_frame>16 weeks</time_frame>
    <description>An inferential test of whether the Treatment Group mean %TBWL is significantly greater than Control Group mean % TBWL at 16 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Incidence of overall procedure or device related Serious Adverse Events</measure>
    <time_frame>24 weeks</time_frame>
    <description>The primary safety endpoint of this clinical investigation is the overall incidence of procedure- or device-related Serious Adverse Events through 24 weeks.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Obesity</condition>
  <condition>Overweight</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to treatment will receive the Elipse device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients randomized to the control arm will receive the sham device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Elipse Device</intervention_name>
    <description>Intervention Device</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Elipse Gastric Balloon System (active)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Elipse Sham Device</intervention_name>
    <description>Control Device</description>
    <arm_group_label>Control</arm_group_label>
    <other_name>Elipse Gastric Balloon System (control)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 22 years and ≤ 65 years of age

          2. BMI ≥30 kg/m2 and ≤ 40 kg/m2

          3. Have signed study specific Informed Consent Form

          4. Willing to comply with study requirements, including follow-up visits

          5. Documented negative pregnancy test in women of childbearing potential.

          6. Women of childbearing potential not intending to become pregnant for the duration of
             study participation. (Note: Women of childbearing potential must not be nursing at the
             time of treatment).

          7. Fully ambulatory without any severe chronic orthopedic disease that requires reliance
             on crutches, walkers or a wheelchair that could preclude exercise during the study.

          8. Confirmed unsuccessful attempts at more conservative weight reduction alternatives,
             such as supervised diet, exercise and behavior modification programs attempted within
             the 24 months preceding enrollment.

        Exclusion Criteria:

          1. Symptomatic congestive heart failure, cardiac arrhythmia or unstable coronary artery
             disease

          2. Pre-existing respiratory disease such as chronic obstructive pulmonary disease (COPD),
             pneumonia or cancer

          3. Previous bariatric or gastric surgery or likely to undergo during study

          4. Use of an intragastric device prior to this study

          5. Chronic pancreatitis or acute pancreatitis within 12 months of enrollment

          6. History of or current small bowel obstructions

          7. History of abdominal and/or pelvic surgery EXCLUDING only ONE of the following
             surgeries that was performed at least 12 months prior to study enrollment: cesarean
             section, diagnostic laparoscopy, laparoscopic appendectomy, laparoscopic
             cholecystectomy. (For example: if a patient has had 2 cesarean sections, or one
             cesarean section and a laparoscopic appendectomy, she would be excluded. If a patient
             had one cesarean section, she may be included)

          8. Diagnosis of autoimmune connective tissue disorder (e.g. lupus, erythematous,
             scleroderma) or immunocompromised

          9. History of genetic or endocrine causes of obesity not adequately controlled by
             medication

         10. History of/or signs and/or symptoms of/or radiographic evidence of esophageal,
             gastric, or duodenal disease including but not limited to hiatal hernias greater than
             or equal to 2 centimeter (cm), paraesophageal hernias, inflammatory diseases, cancer,
             varices, diverticula, gastroparesis, ulcers, stricture/stenosis, achalasia and
             esophagitis

         11. Insulin-dependent diabetes (either Type 1 or Type 2)

         12. Significant acute and/or chronic infections of any kind

         13. Severe coagulopathy, hepatic insufficiency or cirrhosis

         14. Unable or unwilling to discontinue use of aspirin and/or non-steroidal
             anti-inflammatory agents (NSAIDs) at least 14 days prior to Elipse Deployment and
             continuing for 14 days after Elipse excretion

         15. Currently taking the following medications (within 30 days prior to enrollment) and/or
             there is a need or anticipated need for these medications during the study:

             Excluded Medications:

             Systemic corticosteroids Anticoagulant therapy (e.g. warafin, dabigatran) or
             anti-platelet therapy) Immunosuppressive therapy (e.g. azathioprine, cyclosporine)
             Prescription or over the counter weight loss medication(s) Medications known to cause
             significant weight gain or weight loss Narcotics, opiates or benzodiazepines Insulin
             for treatment of diabetes Anti-seizure therapy (e.g. clonazepam, phenytoin)
             Anti-arrhythmics (e.g. amidarone)

         16. History of pulmonary embolism

         17. Has cardiac pacemaker or other electric implantable device

         18. Anemia defined as either:

               1. Hgb &lt; 11 for females, &lt;12 for males

               2. Abnormal red cell indices and iron deficiency

         19. Smoking cessation within 3 months of enrollment or plans to quit smoking during the
             study

         20. Documented total body weight loss of ≥ 5% anytime 6 months preceding enrollment

         21. Residing in a location without ready access to study site medical resources

         22. Inability to walk 200 yards without assistance

         23. Eating disorders including night eating syndrome (NES), bulimia, or binge eating
             disorder

         24. Unwilling to refrain from any reconstructive and/or cosmetic surgery that may affect
             body weight during the study such as mammoplasty and lipoplasty

         25. Current or history of illicit drug use or excessive alcohol use

         26. Enrolled in another investigational study that has not completed the required primary
             endpoint follow-up period (Note: Subjects involved in a long-term surveillance phase
             of another study are eligible for enrollment in this study).

         27. Any conditions that, in the opinion of the investigator, may render the subject unable
             to complete the study with a likely fatal outcome, or lead to difficulties for subject
             compliance with study requirements, or could confound study data.

         28. Patient is not of sufficient medical health as determined by the Investigator to
             participate in the study.

         29. Employees/family members of Allurion Technologies or any of its affiliates or
             contractors

         30. Immediate employees/family members of the Investigator, sub-Investigators, or their
             medical office or practice, or surgical, bariatric or hospital organizations at which
             study procedures may be performed

         31. An immediate family member (by marriage or blood relationship) of another subject
             already enrolled in the study

         32. Positive breath test for H. Pylori

         33. History of or current inflammatory bowel disease (e.g. Crohn's disease, Ulcerative
             Colitis)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ken Malomo</last_name>
    <phone>978-491-8774</phone>
    <email>kmalomo@allurion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Honor Health</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Colorado, Anschutz Health and Wellness Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeanne Anne Breen</last_name>
      <phone>888-978-8399</phone>
    </contact>
    <investigator>
      <last_name>Shelby Sullivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Surgical Specialists of Louisiana</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Perilloux</last_name>
      <phone>888-978-8399</phone>
    </contact>
    <investigator>
      <last_name>Rachel Moore, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Holyoke Medical Center</name>
      <address>
        <city>Holyoke</city>
        <state>Massachusetts</state>
        <zip>01002</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elana Davidson</last_name>
      <phone>888-978-8399</phone>
    </contact>
    <investigator>
      <last_name>Ioannis Raftopoulos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine, Division of Endocrinology, Diabetes and Metabolism</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania Medical Center (UPMC)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Gourash, PhD</last_name>
      <phone>888-978-8399</phone>
    </contact>
    <investigator>
      <last_name>Anita Courcoulas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHI Metabolic and Bariatric Care</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brooke Henson</last_name>
      <phone>888-978-8399</phone>
    </contact>
    <investigator>
      <last_name>Jaime Ponce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MidSouth Bariatrics</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dory Sims</last_name>
      <phone>888-978-8399</phone>
    </contact>
    <investigator>
      <last_name>George Woodman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Center for Surgical Weight Loss</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>UT Physicians Minimally Invasive Surgeons of Texas (UTMIST)</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angielyn Rivera</last_name>
      <phone>888-978-8399</phone>
    </contact>
    <investigator>
      <last_name>Erik Wilson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charlottesville Medical Research Center</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kelly Patterson</last_name>
      <phone>434-817-2442</phone>
    </contact>
    <investigator>
      <last_name>Daniel Pambianco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 3, 2017</study_first_submitted>
  <study_first_submitted_qc>August 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2017</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

